Weekly Digest – January 2025 Weekly Digest – January 2025 09 Jan 2025: Mabwell’s Nectin-4 targeted ADC 9MW2821 combination therapy demonstrates 87.5% ORR and Granted CDE Breakthrough Therapy Designation Mabwell announced that its Nectin-4 targeted ADC (9MW2821) received Breakthrough Therapy […]
Weekly Digest – January 2025 Weekly Digest – January 2025 08 Jan 2025: China’s National Medical Products Administration (NMPA) approves Padcev in combination with Keytruda (Pembrolizumab) for the treatment of advanced bladder cancer China’s NMPA has approved enfortumab vedotin in […]
Weekly Digest – January 2025 Weekly Digest – January 2025 07 Jan 2025: GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives US FDA Breakthrough Therapy Designation in late-line relapsed or refractory osteosarcoma GSK’s B7-H3-targeted antibody-drug conjugate, GSK5764227 (GSK’227), received Breakthrough Therapy Designation […]
